The Therapeutic Goods Administration has granted registration for the protein-based vaccine.
In a statement released on Tuesday, Novavax announced the Therapeutic Goods Administration had granted provisional registration for“As COVID-19 continues to persist and evolve, we are pleased to be able to offer the first protein-based COVID-19 vaccine registered for use as both a primary series and now booster regardless of previous vaccine history,” Novavax chief executive Stanley Erck said.
Results showed a third dose of the Novavax jab produced “increased immune responses comparable to or exceeding levels associated with protection”.The TGA granted provisional registration in January for use of Novavax in people aged 18 and over. The company in May filed for registration of their vaccine to be administered to teenagers aged between 12 and 17.
Institute co-director Ben Marais said one of Labor’s election promises was to establish an Australian Centre for Disease Control.The COVID-19 pandemic had shown Australia lacked a national mechanism to efficiently collate disease surveillance data, co-ordinate responses and conduct rapid applied research to inform policy and guide decision making.